Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles
Метаболомика слюны на основе масс-спектрометрии с капиллярным электрофорезом выявила профили, специфичные для рака полости рта, молочной железы и поджелудочной железы
2009-09-09
SCID: 54.1/xn3jsaja
Discuss with AI
cancer-specific metabolic profilescapillary electrophoresis time-of-flight mass spectrometrymultiple logistic regressionsaliva metabolomicssalivary biomarkers
Figures from the paper
Abstract (AI)
Saliva is a readily accessible and informative biofluid, making it ideal for the early detection of a wide range of diseases including cardiovascular, renal, and autoimmune diseases, viral and bacterial infections and, importantly, cancers. Saliva-based diagnostics, particularly those based on metabolomics technology, are emerging and offer a promising clinical strategy, characterizing the association between salivary analytes and a particular disease. Here, we conducted a comprehensive metabolite analysis of saliva samples obtained from 215 individuals (69 oral, 18 pancreatic and 30 breast cancer patients, 11 periodontal disease patients and 87 healthy controls) using capillary electrophoresis time-of-flight mass spectrometry (CE-TOF-MS). We identified 57 principal metabolites that can be used to accurately predict the probability of being affected by each individual disease. Although small but significant correlations were found between the known patient characteristics and the quantified metabolites, the profiles manifested relatively higher concentrations of most of the metabolites detected in all three cancers in comparison with those in people with periodontal disease and control subjects. This suggests that cancer-specific signatures are embedded in saliva metabolites. Multiple logistic regression models yielded high area under the receiver-operating characteristic curves (AUCs) to discriminate healthy controls from each disease. The AUCs were 0.865 for oral cancer, 0.973 for breast cancer, 0.993 for pancreatic cancer, and 0.969 for periodontal diseases. The accuracy of the models was also high, with cross-validation AUCs of 0.810, 0.881, 0.994, and 0.954, respectively. Quantitative information for these 57 metabolites and their combinations enable us to predict disease susceptibility. These metabolites are promising biomarkers for medical screening. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11306-009-0178-y) contains supplementary material, which is available to authorized users.
Key Findings
1
CE-TOF-MS profiling of saliva from 215 individuals identified 57 principal metabolites associated with oral, breast, and pancreatic cancers.
2
Cancer saliva profiles generally showed higher concentrations of most detected metabolites than samples from periodontal disease patients and healthy controls.
3
Cross-validation supported model performance, yielding AUCs of 0.810 for oral cancer, 0.881 for breast cancer, and 0.994 for pancreatic cancer.
4
Multiple logistic regression distinguished healthy controls from oral, breast, and pancreatic cancer with AUCs of 0.865, 0.973, and 0.993, respectively.
5
The identified metabolites and their combinations provide promising saliva-based biomarkers for disease susceptibility and medical screening.
Research Object
Human saliva samples from individuals with oral, breast, pancreatic cancers, periodontal disease, and healthy controls analyzed by CE-TOF-MS
Research Subject
Cancer- and disease-specific metabolite signatures and their diagnostic discrimination and predictive performance
Publication Details
Publication Date
2009-09-09
Journal
Publisher
ISSN
Cited by
1011
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest